SAN DIEGO, CA--(Marketwired - Jun 19, 2013) - The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, believes investors might be overlooking the potential value of Nuvilex's (
A Phase I/II trial that was conducted at the Rostock Medical University in Germany on 14 patients with advanced inoperable pancreatic cancer produced remarkable results.
In that trial, cells capable of converting the well-known anticancer drug ifosfamide into its cancer-killing form were encapsulated using Nuvilex's live cell encapsulation technology. Then, approximately 300 microcapsules were implanted in the blood supply near the pancreas and therefore the tumor itself. Following this, one-third the normal dosage of ifosfamide was administered.
Historical data for Eli Lilly's Gemzar® (generic is Élan's Gemcitabine IV) with the same type of patients gave a median survival of 22 weeks with a one-year survival rate of 18%. Gemzar® is the only drug approved to date as a single agent for the treatment of advanced inoperable pancreatic cancer.
The patients given Nuvilex's treatment had a median survival of 44 weeks, and 36% survived for one year. With one-third the dosage of chemotherapy coupled with the use of the live cell encapsulation technology, the effectiveness of the treatment was double that of Gemzar®
Annual global revenues for Gemzar® and its generic equivalent are estimated at about $1.4 billion. With an FDA approval for Nuvilex's live cell encapsulation-based treatment, one could argue the market would value the therapy at 2 times the annual sales of Gemzar® -- a therapy worth $3 billion.
At present, the market is valuing the company at about $50 million. While there are many obstacles to an eventual FDA approval including funding, designing, and managing a Phase III study, the longer term upside potential remains intriguing for many investors with a multiyear time horizon.
To read our most recent edition on the long term outlook for Nuvilex, go to:
About The OTC Journal: The OTC Journal is the longest running electronic newsletter committed to small and microcap stocks. Published continuously since 1998, the OTC Journal provides readers with short term trading ideas, long term ongoing coverage of worthy small and microcap companies, and overall market commentary.
The OTC Journal is also an investor relations firm that publishes a newsletter that provides a forum for issuers who wish to advertise their company. To read our publication, including information regarding our compensation, visit www.otcjournal.com. For ongoing updates an opinionated content on Nuvilex and many other small and micro cap stocks, visit www.otcjournal.com and input your email address.
About Nuvilex, Inc. (
- Health Care Industry
- pancreatic cancer
858 793 7908